TG Therapeutics, Inc. (LON:0VGI)

Market Cap	3.09B -15.8%
Revenue (ttm)	395.70M +100.9%
Net Income	332.89M
EPS	2.07
Shares Out	n/a
PE Ratio	9.28
Forward PE	17.71
Dividend	n/a
Ex-Dividend Date	n/a

Volume	61,000
Average Volume	3,827
Open	30.39
Previous Close	37.11
Day's Range	30.39 - 30.39
52-Week Range	27.41 - 38.55
Beta	n/a
RSI	47.77
Earnings Date	Feb 27, 2026

About TG Therapeutics

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company’s development pipeline comprises Ublituximab IV, glyco...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1993
• Employees: 374
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0VGI

Financial Performance

In 2024, TG Therapeutics's revenue was $329.00 million, an increase of 40.80% compared to the previous year's $233.66 million. Earnings were $23.38 million, an increase of 84.52%.

Financial numbers in USD